- call +1-201-465-4211
- email sales@mrinsights.biz
Tuberculosis (TB) is an infectious disease, which is caused by Mycobacterium tuberculosis. These bacteria generally infect human lungs. However, it can infect other body parts/organs as well. Three major types of tuberculosis are found: latent, active, and drug-resistant tuberculosis. Symptoms are not identifiable in case of latent tuberculosis, due to presence of an inactive form of bacteria. In active tuberculosis, symptoms are clearly visible and they can spread from one person to another. Coughing for more than two weeks, chest pain, coughing up blood, chills, fatigue, unintentional weight loss, fever, and loss of appetite are some of the common symptoms of active tuberculosis. HIV/AIDS, severe kidney disease, cancer, diabetes, and malnutrition are some of the key risk factors generally found to be associated with tuberculosis.
Scope of the Report:
This report focuses on the Tuberculosis Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Growing prevalence of multi-drug resistant tuberculosis is driving the tuberculosis drugs market. Drug shortages is a major restraint for the tuberculosis drugs market, especially in low- to medium-income countries of the world. Tuberculosis associated with diseases such as HIV/AIDS and conditions such as obesity is extremely difficult to manage. The tuberculosis drugs market can be segmented based on drug class, disease type, end-user, and region. In terms of drug class, the market can be categorized into first-line therapy, second-line therapy, and combination therapy. Isoniazid, Pyrazinamide, Rifampin, and Ethambutol majorly constitute the first-line therapy for TB; while Streptomycin, Capreomycin, Ethionamide, Levofloxacin, and Gatifloxacin are generally considered as a part of the second-line therapy. Second-line therapy is expected to be a rapidly growing segment of the tuberculosis drugs market.
The worldwide market for Tuberculosis Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Lupin
Otsuka Novel Products
Pfizer
Sanofi
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
First-line Anti-TB Drugs
Second-line Anti-TB Drugs
Market Segment by Applications, can be divided into
Active TB
Latent TB
There are 15 Chapters to deeply display the global Tuberculosis Drug market.
Chapter 1, to describe Tuberculosis Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Tuberculosis Drug, with sales, revenue, and price of Tuberculosis Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Tuberculosis Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Tuberculosis Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Tuberculosis Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Tuberculosis Drug Introduction
1.2 Market Analysis by Type
1.2.1 First-line Anti-TB Drugs
1.2.2 Second-line Anti-TB Drugs
1.3 Market Analysis by Applications
1.3.1 Active TB
1.3.2 Latent TB
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Lupin
2.1.1 Business Overview
2.1.2 Tuberculosis Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Lupin Tuberculosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Otsuka Novel Products
2.2.1 Business Overview
2.2.2 Tuberculosis Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Otsuka Novel Products Tuberculosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Pfizer
2.3.1 Business Overview
2.3.2 Tuberculosis Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Pfizer Tuberculosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sanofi
2.4.1 Business Overview
2.4.2 Tuberculosis Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sanofi Tuberculosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Tuberculosis Drug Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Tuberculosis Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Tuberculosis Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Tuberculosis Drug Manufacturer Market Share in 2017
3.3.2 Top 6 Tuberculosis Drug Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Tuberculosis Drug Market Analysis by Regions
4.1 Global Tuberculosis Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Tuberculosis Drug Sales and Market Share by Regions (2013-2018)
4.1.2 Global Tuberculosis Drug Revenue and Market Share by Regions (2013-2018)
4.2 North America Tuberculosis Drug Sales and Growth Rate (2013-2018)
4.3 Europe Tuberculosis Drug Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Tuberculosis Drug Sales and Growth Rate (2013-2018)
4.5 South America Tuberculosis Drug Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Tuberculosis Drug Sales and Growth Rate (2013-2018)
5 North America Tuberculosis Drug by Countries
5.1 North America Tuberculosis Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Tuberculosis Drug Sales and Market Share by Countries (2013-2018)
5.1.2 North America Tuberculosis Drug Revenue and Market Share by Countries (2013-2018)
5.2 United States Tuberculosis Drug Sales and Growth Rate (2013-2018)
5.3 Canada Tuberculosis Drug Sales and Growth Rate (2013-2018)
5.4 Mexico Tuberculosis Drug Sales and Growth Rate (2013-2018)
6 Europe Tuberculosis Drug by Countries
6.1 Europe Tuberculosis Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Tuberculosis Drug Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Tuberculosis Drug Revenue and Market Share by Countries (2013-2018)
6.2 Germany Tuberculosis Drug Sales and Growth Rate (2013-2018)
6.3 UK Tuberculosis Drug Sales and Growth Rate (2013-2018)
6.4 France Tuberculosis Drug Sales and Growth Rate (2013-2018)
6.5 Russia Tuberculosis Drug Sales and Growth Rate (2013-2018)
6.6 Italy Tuberculosis Drug Sales and Growth Rate (2013-2018)
7 Asia-Pacific Tuberculosis Drug by Countries
7.1 Asia-Pacific Tuberculosis Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Tuberculosis Drug Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Tuberculosis Drug Revenue and Market Share by Countries (2013-2018)
7.2 China Tuberculosis Drug Sales and Growth Rate (2013-2018)
7.3 Japan Tuberculosis Drug Sales and Growth Rate (2013-2018)
7.4 Korea Tuberculosis Drug Sales and Growth Rate (2013-2018)
7.5 India Tuberculosis Drug Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Tuberculosis Drug Sales and Growth Rate (2013-2018)
8 South America Tuberculosis Drug by Countries
8.1 South America Tuberculosis Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Tuberculosis Drug Sales and Market Share by Countries (2013-2018)
8.1.2 South America Tuberculosis Drug Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Tuberculosis Drug Sales and Growth Rate (2013-2018)
8.3 Argentina Tuberculosis Drug Sales and Growth Rate (2013-2018)
8.4 Colombia Tuberculosis Drug Sales and Growth Rate (2013-2018)
9 Middle East and Africa Tuberculosis Drug by Countries
9.1 Middle East and Africa Tuberculosis Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Tuberculosis Drug Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Tuberculosis Drug Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Tuberculosis Drug Sales and Growth Rate (2013-2018)
9.3 UAE Tuberculosis Drug Sales and Growth Rate (2013-2018)
9.4 Egypt Tuberculosis Drug Sales and Growth Rate (2013-2018)
9.5 Nigeria Tuberculosis Drug Sales and Growth Rate (2013-2018)
9.6 South Africa Tuberculosis Drug Sales and Growth Rate (2013-2018)
10 Global Tuberculosis Drug Market Segment by Type
10.1 Global Tuberculosis Drug Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Tuberculosis Drug Sales and Market Share by Type (2013-2018)
10.1.2 Global Tuberculosis Drug Revenue and Market Share by Type (2013-2018)
10.2 First-line Anti-TB Drugs Sales Growth and Price
10.2.1 Global First-line Anti-TB Drugs Sales Growth (2013-2018)
10.2.2 Global First-line Anti-TB Drugs Price (2013-2018)
10.3 Second-line Anti-TB Drugs Sales Growth and Price
10.3.1 Global Second-line Anti-TB Drugs Sales Growth (2013-2018)
10.3.2 Global Second-line Anti-TB Drugs Price (2013-2018)
11 Global Tuberculosis Drug Market Segment by Application
11.1 Global Tuberculosis Drug Sales Market Share by Application (2013-2018)
11.2 Active TB Sales Growth (2013-2018)
11.3 Latent TB Sales Growth (2013-2018)
12 Tuberculosis Drug Market Forecast (2018-2023)
12.1 Global Tuberculosis Drug Sales, Revenue and Growth Rate (2018-2023)
12.2 Tuberculosis Drug Market Forecast by Regions (2018-2023)
12.2.1 North America Tuberculosis Drug Market Forecast (2018-2023)
12.2.2 Europe Tuberculosis Drug Market Forecast (2018-2023)
12.2.3 Asia-Pacific Tuberculosis Drug Market Forecast (2018-2023)
12.2.4 South America Tuberculosis Drug Market Forecast (2018-2023)
12.2.5 Middle East and Africa Tuberculosis Drug Market Forecast (2018-2023)
12.3 Tuberculosis Drug Market Forecast by Type (2018-2023)
12.3.1 Global Tuberculosis Drug Sales Forecast by Type (2018-2023)
12.3.2 Global Tuberculosis Drug Market Share Forecast by Type (2018-2023)
12.4 Tuberculosis Drug Market Forecast by Application (2018-2023)
12.4.1 Global Tuberculosis Drug Sales Forecast by Application (2018-2023)
12.4.2 Global Tuberculosis Drug Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Tuberculosis Drug Picture
Table Product Specifications of Tuberculosis Drug
Figure Global Sales Market Share of Tuberculosis Drug by Types in 2017
Table
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
